$317 Million is the total value of Endurant Capital Management LP's 54 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 160.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $25,768,000 | +74.1% | 401,434 | +37.5% | 8.12% | +52.8% |
| ANTM | Buy | ANTHEM INC | $24,779,000 | +302.3% | 82,043 | +219.8% | 7.81% | +253.1% |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $20,219,000 | +22.9% | 1,218,029 | +23.1% | 6.37% | +7.9% |
| ABC | Buy | AMERISOURCEBERGEN CORP | $18,604,000 | +114.2% | 218,820 | +107.4% | 5.86% | +88.0% |
| LH | Buy | LABORATORY CORP AMER HLDGS | $18,278,000 | +22.3% | 108,043 | +21.4% | 5.76% | +7.3% |
| CI | Buy | CIGNA CORP NEW | $16,510,000 | +50.8% | 80,739 | +12.0% | 5.20% | +32.4% |
| BDX | Buy | BECTON DICKINSON & CO | $15,538,000 | +178.4% | 57,131 | +159.0% | 4.90% | +144.4% |
| EHC | Buy | ENCOMPASS HEALTH CORP | $11,297,000 | +1400.3% | 163,092 | +1271.4% | 3.56% | +1218.1% |
| REGN | New | REGENERON PHARMACEUTICALS | $10,284,000 | – | 27,390 | +100.0% | 3.24% | – |
| SIBN | New | SI BONE INC | $10,114,000 | – | 470,429 | +100.0% | 3.19% | – |
| IQV | New | IQVIA HLDGS INC | $7,692,000 | – | 49,781 | +100.0% | 2.42% | – |
| HRC | New | HILL ROM HLDGS INC | $7,475,000 | – | 65,843 | +100.0% | 2.36% | – |
| IRTC | New | IRHYTHM TECHNOLOGIES INC | $6,102,000 | – | 89,614 | +100.0% | 1.92% | – |
| EVH | New | EVOLENT HEALTH INCcl a | $5,406,000 | – | 597,303 | +100.0% | 1.70% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $5,139,000 | – | 39,822 | +100.0% | 1.62% | – |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $4,665,000 | +197.9% | 168,546 | +95.8% | 1.47% | +161.6% |
| MDRX | New | ALLSCRIPTS HEALTHCARE SOLUTN | $4,397,000 | – | 447,986 | +100.0% | 1.38% | – |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $3,884,000 | +103.2% | 2,055,069 | +16.1% | 1.22% | +78.4% |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $3,624,000 | – | 66,157 | +100.0% | 1.14% | – |
| FLDM | Buy | FLUIDIGM CORP DEL | $3,601,000 | +96.6% | 1,034,633 | +161.5% | 1.13% | +72.6% |
| XRAY | New | DENTSPLY SIRONA INC | $3,210,000 | – | 56,725 | +100.0% | 1.01% | – |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $3,106,000 | +57.7% | 29,710 | +73.4% | 0.98% | +38.3% |
| BAX | New | BAXTER INTL INC | $2,856,000 | – | 34,151 | +100.0% | 0.90% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $2,475,000 | – | 214,823 | +100.0% | 0.78% | – |
| SILK | New | SILK ROAD MEDICAL INC | $2,072,000 | – | 51,303 | +100.0% | 0.65% | – |
| CNMD | Buy | CONMED CORP | $2,006,000 | +59.1% | 17,940 | +36.8% | 0.63% | +39.5% |
| AHCO | New | ADAPTHEALTH CORP | $1,843,000 | – | 167,858 | +100.0% | 0.58% | – |
| PRTA | Buy | PROTHENA CORP PLC | $1,743,000 | +157.5% | 110,135 | +27.5% | 0.55% | +125.9% |
| MCK | New | MCKESSON CORP | $1,438,000 | – | 10,396 | +100.0% | 0.45% | – |
| MGNX | New | MACROGENICS INC | $1,337,000 | – | 122,900 | +100.0% | 0.42% | – |
| TNDM | New | TANDEM DIABETES CARE INC | $1,273,000 | – | 21,361 | +100.0% | 0.40% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $1,153,000 | – | 11,151 | +100.0% | 0.36% | – |
| DVA | New | DAVITA INC | $901,000 | – | 12,002 | +100.0% | 0.28% | – |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $493,000 | -9.7% | 238,207 | +26.6% | 0.16% | -20.9% |
| STRO | New | SUTRO BIOPHARMA INC | $359,000 | – | 32,666 | +100.0% | 0.11% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $303,000 | – | 13,768 | +100.0% | 0.10% | – |
| PTI | New | PROTEOSTASIS THERAPEUTICS INcall | $108,000 | – | 47,400 | +100.0% | 0.03% | – |
| ACRS | New | ACLARIS THERAPEUTICS INCcall | $94,000 | – | 376,200 | +100.0% | 0.03% | – |
| SELB | New | SELECTA BIOSCIENCES INC | $61,000 | – | 25,788 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.